Comorbidity, Physical Function, and Quality of Life in Older Adults with Acute Myeloid Leukemia

Current Geriatrics Reports
Susan StoreyAshley Leak Bryant

Abstract

To describe the pathology, impact of comorbidities, functional limitations, symptoms, and quality of life (QOL) related to treatment of acute myeloid leukemia (AML) in older adults. AML is a rare aggressive hematologic disease that occurs most often in older adults. The prognosis for older patients with AML is markedly worse due to genetic mutations and patient characteristics such as comorbidities and functional limitations. Patient characteristics may influence treatment decisions, as well as impact symptoms, functional ability, health-related outcomes and (QOL). As the population continues to age, the number of people diagnosed with AML is expected to increase. Better management of comorbidities is imperative to improving QOL and other treatment related outcomes. Prospective, longitudinal and multi-site studies are warranted to further understand the interaction between these characteristics on symptoms, outcomes and QOL.

References

Dec 3, 2002·The American Journal of Occupational Therapy : Official Publication of the American Occupational Therapy Association·Mary Law
Dec 23, 2003·Journal of the American Geriatrics Society·Kenneth H ChuangC Seth Landefeld
Nov 4, 2004·JAMA : the Journal of the American Medical Association·Thomas M GillZhenchao Guo
Apr 13, 2007·The New England Journal of Medicine·Lillian L Siu
May 10, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Elihu Estey
Aug 15, 2009·Integrative Cancer Therapies·Claudio L BattagliniThomas Shea
Nov 12, 2009·Current Sports Medicine Reports·Karen M MustianJennifer Carroll
Jan 6, 2010·Journal of Gerontological Nursing·Marilyn J HammerDonna L Berry
May 5, 2010·Oncology Nursing Forum·Barbara B Rogers
Jun 18, 2010·CA: a Cancer Journal for Clinicians·Edward GiovannucciDouglas Yee
Jun 19, 2010·Medicine and Science in Sports and Exercise·Kathryn H SchmitzUNKNOWN American College of Sports Medicine
Jun 19, 2010·Biogerontology·T FulopG Pawelec
Jan 10, 2012·The Journal of Clinical Endocrinology and Metabolism·Guillermo E UmpierrezUNKNOWN Endocrine Society
Apr 6, 2012·Diabetologia·A G RenehanUNKNOWN Diabetes and Cancer Research Consortium
May 4, 2012·Cancer Causes & Control : CCC·Adedayo A OnitiloSuhail A Doi
Jun 20, 2012·Journal of Geriatric Oncology·Lisa K SprodKaren M Mustian
Jul 10, 2012·Haematologica·Betul Oran, Daniel J Weisdorf
Jan 11, 2013·The New England Journal of Medicine·Harlan M Krumholz
Mar 23, 2013·Cancer Nursing·Denise Soltow HersheyAlexander von Eye
Apr 13, 2013·Revista brasileira de hematologia e hemoterapia·Carolina do Nascimento MatiasVera Magalhães
Jan 1, 2011·Journal of Geriatric Oncology·Heidi D KlepinShannon L Mihalko
Jul 28, 2013·Leukemia & Lymphoma·Aziz Nazha, Farhad Ravandi
Nov 20, 2013·BMC Pregnancy and Childbirth·Lee K TaylorJonathan Morris
Nov 28, 2013·Academic Medicine : Journal of the Association of American Medical Colleges·Christina M PuchalskiAmy Butler
Jan 30, 2014·Longevity & Healthspan·Daniel BaylisHelen C Roberts
Apr 26, 2014·Current Opinion in Immunology·Graham PawelecEvelyna Derhovanessian
Jul 30, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Heidi D KlepinTimothy S Pardee
Aug 28, 2014·Oncology Nursing Forum·Jill M OlaussonVeronica Brady
Sep 18, 2014·European Journal of Oncology Nursing : the Official Journal of European Oncology Nursing Society·Susan Storey, Diane Von Ah
Oct 31, 2014·Oncology Nursing Forum·Veronica J BradyGeri LoBiondo-Wood
Feb 20, 2015·Hematology·Eunice S Wang
Mar 26, 2015·Oncology Nursing Forum·Ashley Leak BryantBryce B Reeve
May 6, 2015·Current Hematologic Malignancy Reports·Heidi D Klepin
Oct 3, 2015·Journal of Cancer Survivorship : Research and Practice·Pauline A J VissersMelissa S Y Thong

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Related Papers

Best Practice & Research. Clinical Rheumatology
Jan HartvigsenManuela Ferreira
Neonatal Network : NN
K Thomas
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation
Kathleen L GradyWilliam Piccione
© 2022 Meta ULC. All rights reserved